BioSpace News Archive

Aimmune’s peanut allergy treatment is one-step closer to approval following strong support from the Allergenic Products Advisory Committee, which overwhelmingly recommended approval of Palforzia, the proposed trade name of the investigational oral treatment, AR101.

The amount of recognition workers receive can be linked to employee turnover rates.

Working with a new class of cancer drugs called G12C KRAS inhibitors, researchers at the Francis Crick Institute and The Institute of Cancer Research (ICR), London, developed drug combinations to stay ahead of drug resistant tumors.

A new study shows that approximately half of clinical trials that supported approvals for new cancer drugs in Europe were judged to be at high risk of bias, meaning that some treatment effects might have been exaggerated.

Here are the keys to a smooth long distance job search. Follow these simple guidelines to avoid many of the stresses of job hunting from a distance.

House Speaker Nancy Pelosi unveiled her plan to lower the prices on up to 250 prescription drugs covered by government-backed plans such as Medicare.

Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.

AveXis presented new interim data from the Phase III SPR1NT trial of Zolgensma (onasemnogene abeparvovec-xioi) in spinal muscular atrophy (SMA) Type 1.

Biotech and pharma companies from across the globe strengthen their leadership teams and boards of directors with this week’s appointments.

JenaValve Technology, Inc., a developer of a novel transcatheter aortic valve replacement (TAVR) system for the treatment of aortic valve disease, today announced the appointment of two veteran medical device executives Vinny Podichetty, MD, MS as Vice President, Clinical Affairs, and Jeff Thiel as Vice President, Operations, effective immediately.